Qilian International Holding Group Ltd. Announces Trading Ticker Symbol to “BGM”
CHENGDU, China, Aug. 13, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ: QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that effective on August 11, 2024, its Class A ordinary shares will begin trading on the Nasdaq Capital Market under the ticker symbol "BGM". The new ticker symbol will replace the Company's...
Sinch AI Used to Safely Pre-Triage Patients
STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Sinch (Sinch AB (publ) – XSTO: SINCH), which is pioneering the way the world communicates through its Customer Communications Cloud, is excited to announce that MINDD, a Dutch medical technology company, has selected Sinch to develop an advanced AI-driven solution to safely pre-triage patients, significantly alleviating the overwhelming burden on medical practices. In...
Australian biotech incubator Proto Axiom announces $20M Series B first close
$20M unlocked for opportunities in Australian biotech innovation, valuing Proto Axiom at $90M SYDNEY, Aug. 13, 2024 /PRNewswire/ -- Proto Axiom, the Australian biomedical technology incubator has today announced a $20 million first close of its targeted $30 million Series B, to bolster Australia's biotechnology (biotech) sector through increased intellectual property (IP) retention. The Series B first close...
Registrational Phase III Study of Lisaftoclax in Newly-Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome Cleared by China CDE
ROCKVILLE, Md. and SUZHOU, China, Aug. 13, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for malignancies, announced today it has been cleared by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) to initiate a...
Chang Gung Cancer Proton Therapy Achieves Breakthrough
Research Confirms Effective Control of Large Liver Cancer, Doubling Survival Time Published in the International Journal of Radiation Oncology TAOYUAN, Aug. 13, 2024 /PRNewswire/ -- With cancer incidence on the rise, proton therapy has emerged as one of the most powerful tools in cancer treatment. Chang Gung Memorial Hospital, Linkou, the first on the island to introduce proton therapy,...
Biosyngen’s BRG01 Receives FDA Approval for Phase II Clinical Trial
SINGAPORE, Aug. 13, 2024 /PRNewswire/ -- Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial. This marks the first cell therapy to enter Phase lI trials in both the U.S....
Pantai Hospital Kuala Lumpur Introduces Outpatient Parenteral Antimicrobial Therapy (OPAT) for Improved Patient Care
KUALA LUMPUR, Malaysia, Aug. 12, 2024 /PRNewswire/ -- Pantai Hospital Kuala Lumpur (PHKL) has officially introduced its Outpatient Parenteral Antimicrobial Therapy (OPAT) service, offering an innovative treatment option that enhances patient care. Pantai Hospital Kuala Lumpur OPAT patient being outfitted with a Baxter elastomeric pump bottle that infuses antibiotics over a 24-hour period Reaffirming PHKL's commitment in...
AI in the IVF Process is the Standard of Care at Virtus Fertility Centre Singapore
The technology developed by Virtus Health's scientists contributes to IVF medicine by shortening the time to a successful pregnancy and improving overall success rates. SINGAPORE, Aug. 13, 2024 /PRNewswire/ -- Virtus Fertility Centre Singapore (VFCS) announced that artificial intelligence (AI), used as a predictive tool to identify the most viable embryo in the...
MediPortal Introduces AI for Practice Management in Australia
PERTH, Australia, Aug. 13, 2024 /PRNewswire/ -- MediPortal PTY LTD. (MediPortal) has launched an AI-powered practice intelligence platform for Australian medical practices, aiming to enhance efficiency and patient care. Developed as the brainchild of a practising general practitioner, this innovative software integrates with Best Practice Software, extending its capabilities across Australia and New Zealand. MediPortal - AI...
Lynk Pharmaceuticals Announces Positive Results from Phase 1b Clinical Study of LNK01004 for the Treatment of Atopic Dermatitis
HANGZHOU, China and SHANGHAI and BOSTON, Aug. 13, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced positive results from its Phase 1b clinical study of LNK01004, a skin restricted, soft pan-JAK inhibitor, for the treatment of atopic dermatitis. The study is a randomized, double-blind, placebo-controlled, multicenter clinical...
